Clinical Trials

Zafgen is developing a range of potential first-in-class therapies for type 2 diabetes and other complex metabolic conditions.

ZGN-1061 for the treatment of type 2 diabetes:  ZGN-1061 is an investigational MetAP2 inhibitor for the treatment of type 2 diabetes. Our ongoing Phase 2 clinical trial is designed to confirm its pharmacokinetic profile and evaluate safety, tolerability, and glucose-lowering efficacy. Enrollment in the trial is complete.

ZGN-1258 for Prader-Willi syndrome:  Zafgen is initiating GLP toxicology studies, in preparation for filing an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA). The company plans to first initiate a Phase 1 clinical trial in of ZGN-1258 in non-PWS participants, and then select a target dose range prior to initiating clinical trials for people with PWS.

For more information or questions about trial participation, please contact us at